• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc. (Amendment)

    2/14/24 10:09:20 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CYCC alert in real time by email
    SC 13G/A 1 cycc_13gv3.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G/A

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 2)*

     

     

    Cyclacel Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value
    (Title of Class of Securities)
     
    23254L603
    (CUSIP Number)
     
    December 31, 2023
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)
    o Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 23254L60313G/APage 1 of 9 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Dellora Investments Master Fund LP

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Cayman Islands

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    0

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

     

     

    CUSIP No. 23254L60313G/APage 2 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Dellora Investments LP

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    0

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC

     

           
    CUSIP No. 23254L60313G/APage 3 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kevin Pyun

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    0

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    0

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    0

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    0%

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           
    CUSIP No. 23254L60313G/APage 4 of 9 Pages

     

    AMENDMENT NO. 2 TO SCHEDULE 13G

     

    Reference is hereby made to the statement on Schedule 13G filed with the Securities and Exchange Commission by the Reporting Persons with respect to the Common Stock of the Issuer on August 22, 2022 and February 13, 2023 (as so amended, the “Schedule 13G“). Terms defined in the Schedule 13G are used herein as so defined.

     

    The following Items of the Schedule 13G are amended and restated to read in their entirety as follows:

     

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (e) [x] An investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E)

    (g) [x] Parent Holding Company or control person in accordance with Rule 13d-1(b)(1)(ii)(G)

    CUSIP No. 23254L603 13G/A Page 5 of 9 Pages

     

     

     

    Item 4.Ownership

     

    (i)Dellora Investments Master Fund LP

     

    (a)Amount beneficially owned: 0

     

    (b)Percent of class: 0%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 0

     

    (ii)Dellora Investments LP

     

    (a)Amount beneficially owned: 0

     

    (b)Percent of class: 0%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 0

     

    (iii)Kevin Pyun

     

    (a)Amount beneficially owned: 0

     

    (b)Percent of class: 0%

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 0

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 0

     

    CUSIP No. 23254L603 13G/A Page 6 of 9 Pages

     

     

    Note 1:

     

    Dellora Investments LP is an investment adviser that is registered as an Exempt Reporting Adviser with the Securities and Exchange Commission. Dellora Investments LP, which serves as the investment manager to investment funds, including but not limited to, Dellora Investments Master Fund LP (the "Fund"), may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Mr. Kevin Pyun, as Principal of Dellora Investments LP, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Dellora Investments LP and Mr. Pyun expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Dellora Investments LP or Mr. Pyun are the beneficial owner of any of the securities reported herein.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ X ].

      

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

     

    See Not Applicable.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

      

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable.

      

    CUSIP No. 23254L603 13G/A Page 7 of 9 Pages

     

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: February 14, 2024

     

     

     

    DELLORA INVESTMENTS MASTER FUND LP

    By: Dellora Investments Fund GP LLC, its General Partner

    By: /s/ Kevin Pyun

    Name: Kevin Pyun

    Title: Principal

     

     

    DELLORA INVESTMENTS LP

    By: Dellora Investments GP LLC, its General Partner

    By: /s/ Kevin Pyun

    Name: Kevin Pyun

    Title: Principal

     

     

    KEVIN PYUN

    By: /s/ Kevin Pyun

     

     

    CUSIP No. 23254L603 13G/A Page 8 of 9 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated:  February 14, 2024
         

    DELLORA INVESTMENTS MASTER FUND LP

    By: Dellora Investments Fund GP LLC, its General Partner

    By: /s/ Kevin Pyun

    Name: Kevin Pyun

    Title: Principal

     

     

    DELLORA INVESTMENTS LP

    By: Dellora Investments GP LLC, its General Partner

    By: /s/ Kevin Pyun

    Name: Kevin Pyun

    Title: Principal

     

     

    KEVIN PYUN

    By: /s/ Kevin Pyun

     

     

     

     

    CUSIP No. 23254L603 13G/A Page 9 of 9 Pages

    Get the next $CYCC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CYCC

    DatePrice TargetRatingAnalyst
    7/18/2022$17.00Outperform
    Oppenheimer
    More analyst ratings

    $CYCC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Fitters Diversified Berhad claimed ownership of 699,158 shares (SEC Form 3)

    3 - Bio Green Med Solution, Inc. (0001130166) (Issuer)

    9/16/25 3:31:42 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Kua Khai Loon sold $133,569 worth of shares (19,054 units at $7.01), decreasing direct ownership by 5% to 385,411 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/10/25 3:09:51 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Ong Yee Lung acquired 186,465 shares, increasing direct ownership by 86% to 404,465 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    9/4/25 4:00:15 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd.

    KUALA LUMPUR, Malaysia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Bio Green Med Solution, Inc. (NASDAQ:BGMS, NASDAQ:BGMSP) ("Bio Green Med" or the "Company"), a company engaged in diversified industries, today announced that it has closed the previously announced transaction (the "Exchange Transaction") to acquire Fitters Sdn. Bhd. ("Fitters"), a Malaysia private limited company and wholly-owned subsidiary of FITTERS Diversified Berhad, a Malaysian publicly listed company ("Fitters Parent"). Following the closing of the Exchange Transaction, which was approved by the Company's stockholders during a Special Meeting that took place on September 4, 2025, Fitters became a wholly-owned subsidiary of t

    9/12/25 6:00:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB

             - Biliary tract cancer (BTC) or cholangiocarcinoma is an aggressive tumor with poor prognosis - KUALA LUMPUR, Malaysia, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative cancer medicines, highlighted a preclinical study from independent investigators titled, "Evaluation of antitumor effects of plogosertib, PLK1 inhibitor in biliary tract cancer with BUBR1 as a potential biomarker" in the journal, Cancer Research, previously reported in a poster at the American Association of Cancer Research 2025 annual meeting.1 The investigators found that several BT

    8/4/25 6:50:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer resumed coverage on Cyclacel Pharma with a new price target

    Oppenheimer resumed coverage of Cyclacel Pharma with a rating of Outperform and set a new price target of $17.00

    7/18/22 9:13:15 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer initiated coverage on Cyclacel Pharmaceuticals with a new price target

    Oppenheimer initiated coverage of Cyclacel Pharmaceuticals with a rating of Outperform and set a new price target of $17.00

    4/30/21 6:36:41 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rombotis Spiro George bought $20,122 worth of shares (6,070 units at $3.31), increasing direct ownership by 10% to 68,658 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:23 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mcbarron Paul bought $6,252 worth of shares (1,886 units at $3.31), increasing direct ownership by 6% to 33,378 units (SEC Form 4)

    4 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Issuer)

    12/26/23 4:05:25 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    SEC Filings

    View All

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Bio Green Med Solution, Inc. (0001130166) (Filer)

    9/16/25 4:05:31 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by Cyclacel Pharmaceuticals Inc.

    425 - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    9/12/25 6:09:33 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Cyclacel Pharmaceuticals, Inc. (0001130166) (Filer)

    9/12/25 6:07:02 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Leadership Updates

    Live Leadership Updates

    View All

    Cyclacel Pharmaceuticals Reports Fourth Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., April 02, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, "Cyclacel" or the "Company")), a biopharmaceutical company developing innovative medicines, today announced fourth quarter financial results and provided a business update. "As part of Cyclacel's efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 (PLK 1) inhibitor for treatment of advanced cancers and hematological malignancies, which we acquired on March 10, 2025, from Cyclacel Limited, our wholly-owned subsidiary that is currently in liquidation," said Datuk Dr. Doris Wong Sing Ee, Chief Executive Officer

    4/2/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Announces the Appointment of Brian Schwartz, M.D. as Chief Medical Officer

    BERKELEY HEIGHTS, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", ))), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today that Brian Schwartz, M.D. will assume the role of interim Chief Medical Officer ("CMO") of the Company effective immediately. Dr. Schwartz will succeed Mark Kirschbaum, M.D., whose employment was terminated by the Company. "We are delighted to have Brian join Cyclacel as CMO. His extensive clinical and product development experience in oncology and hematology further adds to the strengths of our team and will support our efforts

    1/30/24 9:15:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reviews 2020 Achievements and Announces Key Business Objectives for 2021

    – Anticancer Activity of Fadraciclib Monotherapy in Patients with MCL1 Amplified Solid Tumors–– Appointment of Mark Kirschbaum, M.D. as Chief Medical Officer –– $7 Million Strategic Investment by Fundamental Investor Acorn Bioventures– BERKELEY HEIGHTS, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today provided a business update reviewing 2020 achievements and outlining the Company’s key business objectives for 2021. The Company will present at Biotech Showcase™ Digital 2021 taking place virtually from Januar

    1/11/21 7:46:19 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Financials

    Live finance-specific insights

    View All

    Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update

    KUALA LUMPUR, Malaysia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its second quarter financial results and provided a business update. Highlights of the second quarter ended June 30, 2025, or in some cases shortly thereafter, include: In April, the Company announced that the Board of Directors of the Company declared a quarterly cash dividend of $0.15 per share on the Company's 6% Convertible Exchangeable Preferred Stock, which cash dividend was paid on May 1, 2025, to holders of 6% Convertible Exchangeable P

    8/13/25 4:05:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CYCLACEL PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

    KUALA LUMPUR, MALAYSIA, May 15, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced its first quarter financial results and provided a business update. "As part of the Company's efforts to reduce operating costs it has determined to focus on the development of the plogosertib ("plogo") clinical program only. Accordingly, on March 10, 2025, the Company repurchased certain assets related to plogo from Cyclacel Limited for approximately $0.3 million in cash, to allow us to continue our efforts on developing an alternative salt, oral formulation of

    5/15/25 12:50:00 AM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

    BERKELEY HEIGHTS, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative medicines, today announced third quarter financial results and provided a business update. "We were pleased to report initial safety and efficacy data from twelve patients with advanced solid tumors enrolled in the Phase 2 part of the 065-101, proof of concept, clinical study of fadraciclib as a single agent as a poster presentation at the 2024 EORTC-NCI-AACR 36th Symposium on Molecular Targets and Cancer Therapeutics ("Triple Meeting"), in Barcelona, Spain. The patients were enrolled in

    11/12/24 4:45:00 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CYCC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc.

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 7:21:58 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Cyclacel Pharmaceuticals Inc.

    SC 13G - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    11/14/24 3:27:04 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Cyclacel Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Cyclacel Pharmaceuticals, Inc. (0001130166) (Subject)

    2/14/24 4:31:09 PM ET
    $CYCC
    Biotechnology: Pharmaceutical Preparations
    Health Care